Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PILOT-STUDY ON THE EFFICACY OF ESCALATING DOSAGE OF ALPHA-INTERFERON FOR CHRONIC HEPATITIS-C IN HIV-INFECTED PATIENTS
Autore:
SORIANO V; BRAVO R; GARCIASAMANIEGO J; ORTEGA E; GONZALEZ J; COLMENERO M; CASTILLA J; CASTRO A; SUAREZ D;
Indirizzi:
C RAFAEL CALVO 7,2 A MADRID SPAIN INST SALUD CARLOS III,SERV INFECT DIS & HEPATOL MADRID SPAIN HOSP GEN UNIV,SERV INTERNAL MED VALENCIA SPAIN HOSP LA PAZ,AIDS UNIT SEVILLE SPAIN HOSP VIRGEN MACARENA,UNIDAD INFECCIOSAS SEVILLE SPAIN INST SALUD CARLOS III,CTR NACL EPIDEMIOL MADRID SPAIN HOSP JUAN CANALEJO,MED INTERNA SERV LA CORUNA SPAIN HOSP ARQUITECTO MARCIDE,MED INTERNA SERV EL FERROL SPAIN
Titolo Testata:
The Journal of infection
fascicolo: 3, volume: 35, anno: 1997,
pagine: 225 - 230
SICI:
0163-4453(1997)35:3<225:APOTEO>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B HEPATITIS; CHRONIC NON-A; CONTROLLED TRIAL; LIVER-DISEASE; ALFA THERAPY; SERUM; RNA; PROGRESSION; PREDICTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
V. Soriano et al., "A PILOT-STUDY ON THE EFFICACY OF ESCALATING DOSAGE OF ALPHA-INTERFERON FOR CHRONIC HEPATITIS-C IN HIV-INFECTED PATIENTS", The Journal of infection, 35(3), 1997, pp. 225-230

Abstract

Chronic liver disease caused by hepatitis C virus (HCV) seems to present a more accelerated course in HIV-infected patients, leading to cirrhosis and liver failure in a shorter period of time than in HIV-negative individuals. As efforts to increase life expectancy in HIV-infected people progress, substantial morbidity and mortality from HCV infection is likely to arise amongst subjects infected parenterally, such asinjecting drug users, haemophiliacs and transfusion recipients, Preliminary results have suggested that alpha-interferon (IFN) treatment allows higher rates of response in HIV-infected patients with higher CD4 lymphocyte counts, suggesting a primary dependence of IFN on a preserved immune system in order to act appropriately, In an open, multicentre, prospective trial we analysed whether the use of larger doses of IFN, through an escalating schedule, might overcome the limits imposedby immune dysfunction, An interim analysis performed in 29 patients concluded that escalating the dosage did not improve the rate of response to IFN, In fact, only one (8.3%) out of 12 patients without response after 3 months of being on IFN therapy achieved response after the dosage was increased from 5 MU to 8 MU sc three times a week, Moreover,he relapsed 3 months after completion of treatment for 1 year.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 16:41:26